Emergent BioSolutions Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EBS New York 2836 www.emergentbiosolutions.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Emergent BioSolutions Inc.

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy - May 28th, 2026 2:01 pm
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization - May 20th, 2026 2:43 pm
Emergent BioSolutions to Participate in Upcoming Investor Conferences - May 20th, 2026 5:30 am
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] - May 18th, 2026 6:59 am
Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved - May 2nd, 2026 8:29 am
Emergent BioSolutions Inc. Q1 2026 Earnings Call Summary - May 1st, 2026 6:30 am
Emergent Biosolutions Q1 Earnings Call Highlights - May 1st, 2026 5:18 am
Emergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights: Strong Revenue and Strategic ... - May 1st, 2026 1:19 am
Emergent BioSolutions Reports First Quarter 2026 Financial Results - Apr 30th, 2026 2:30 pm
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox - Apr 30th, 2026 5:55 am
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - Apr 29th, 2026 5:35 am
Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives - Apr 29th, 2026 4:53 am
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States - Apr 28th, 2026 6:01 am
How The Emerging Narrative On Emergent BioSolutions (EBS) Is Shifting After The Earnings Miss - Apr 23rd, 2026 4:05 am
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026 - Apr 16th, 2026 2:05 pm
Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility - Apr 16th, 2026 2:05 pm
Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program - Apr 9th, 2026 2:25 pm
McKinsey Will Add $125 Million to Purdue's $7 Billion Bankruptcy Settlement - Apr 9th, 2026 12:34 pm
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness - Apr 7th, 2026 6:05 am
A Look At Erste Group Bank’s (WBAG:EBS) Valuation Following Recent Share Price Softness - Apr 3rd, 2026 5:12 am